PURE Bioscience reports Q3 net loss of $624k; CEO Bartlett to retire July 31, Kitchell to succeed

PURE BIOSCIENCE, INC.

2026-Q3 EPS reported -$0.02 revenue$1,656,000

Q3 net product sales $506k (+3.5% YoY); net loss $624k vs $580k YoY; EPS ($0.01).
Nine-month net product sales $1.66M (+15.4% YoY); net loss $1.87M vs $2.07M YoY.
CEO Robert Bartlett retiring July 31, 2026; President Jeff Kitchell appointed CEO effective Aug 1.
Director Bernard Blotner leaving board due to health; no replacement named.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PURE BIOSCIENCE, INC. reported the nine months ended April 30, 2026 results: revenue $1,656,000, net income $1,873,000, EPS ($0.02).

Period: the nine months ended April 30, 2026
Revenue: $1,656,000
Net income: $1,873,000
EPS: ($0.02)
Result: reported results

Exact text from the filing

per share was ($0.01) for the fiscal third quarters ended April 30, 2026 and 2025, respectively. Summary of Results of Operations – Prior Nine Months ● Net product sales were $1,656,000 and $1,435,000 for the nine months ended April 30, 2026 and 2025, respectively. The $221,000 increase was attributable to higher sales across our end-user network. ● Net loss

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PURE BIOSCIENCE, INC. reported the fiscal third quarter ended April 30, 2026 results: revenue $506,000, net income $624,000, EPS ($0.01).

Period: the fiscal third quarter ended April 30, 2026
Revenue: $506,000
Net income: $624,000
EPS: ($0.01)
Result: reported results

Exact text from the filing

) antimicrobial, today reported financial results for the fiscal third quarter ended April 30, 2026. Summary of Results of Operations – Third Quarter ● Net product sales were $506,000 and $489,000 for the fiscal third quarters ended April 30, 2026 and 2025, respectively. The $17,000 increase was attributable to higher sales across our distribution network. ●

View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

PURE BIOSCIENCE, INC. filing history →

Source: SEC EDGAR

accession 0001493152-26-028686

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.